Welcome to our dedicated page for Aehr Test Sys SEC filings (Ticker: AEHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aehr Test Systems (NASDAQ: AEHR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-based supplier of semiconductor test and burn-in systems, Aehr uses these filings to report on financial performance, corporate governance, equity compensation plans, and other material events.
Investors can review current reports on Form 8-K, where Aehr discloses items such as quarterly and annual financial results, amendments to equity incentive and employee stock purchase plans, and outcomes of shareholder votes at its annual meetings. For example, recent 8-K filings describe the approval of amendments to the 2023 Equity Incentive Plan and the Amended and Restated 2006 Employee Stock Purchase Plan, as well as the ratification of the company’s independent registered public accounting firm.
The company’s proxy statement on Schedule DEF 14A provides detail on director elections, executive compensation proposals, advisory votes on pay and pay frequency, and the matters submitted to shareholders at the annual meeting. These documents help investors understand Aehr’s board structure, compensation programs, and shareholder voting results.
On Stock Titan, Aehr’s filings are updated in near real time from EDGAR. Users can access 8-Ks for earnings announcements and other material events, proxy materials for governance and compensation information, and related exhibits referenced in those filings. AI-powered summaries highlight key points, allowing readers to quickly see how developments in Aehr’s semiconductor test and burn-in business—spanning FOX wafer-level systems and Sonoma, Echo, and Tahoe package-level platforms—are reflected in its official disclosures.
Form 4 overview: On 07/02/2025, Alistair N. Sporck, Vice-President of the Contractor Business Unit at Aehr Test Systems (AEHR), reported several equity transactions.
- Restricted Stock Units granted: 9,253 RSUs with quarterly vesting over four years (1/16 per quarter) and 2,276 RSUs with 25% immediate vesting and the balance vesting quarterly over three years. Both grants were recorded at a cost basis of $0.
- Tax-withholding transaction: 305 shares were automatically withheld at $15.13 to cover taxes on vested RSUs; this is classified as a disposition code “F” and does not represent an open-market sale.
- Post-transaction ownership: Sporck now directly owns 34,120 common shares and indirectly controls 3,993 shares through a trust.
- The filing notes an additional 936 shares received on 04/25/2025 from the termination of the company’s ESOP, included in the total.
No derivative securities were reported. The transactions reflect routine executive compensation and tax-withholding activity, with no cash proceeds to the insider and no change to the company’s share count.
Form 4 filing overview – AEHR Test Systems (AEHR)
Executive Vice President Alberto Salamone reported two equity transactions dated 02 July 2025:
- Acquisition: 18,126 common shares were acquired at $0.00, indicating the vesting/grant of restricted stock units (RSUs). Following this line item, his direct ownership increased to 80,976 shares.
- Tax-withholding disposition: 2,441 shares were automatically withheld at $15.13 per share (transaction code “F”). This was not an open-market sale but satisfied payroll tax obligations tied to the RSU vesting.
Ending beneficial ownership: 78,535 common shares, which still includes unvested RSUs referenced in footnote 3.
The RSU schedule (footnote 1) states that 25 % vests immediately, with the remaining 75 % vesting quarterly over three years, aligning Salamone’s incentives with long-term shareholder value.
No derivative securities were reported. The filing signals continued insider equity exposure with only routine, non-discretionary share withholding. There is no indication of open-market selling pressure.
Form 4 overview – Aehr Test Systems (AEHR)
On 07/02/2025, Executive Vice President Alberto Salamone reported the acquisition of 6,609 shares of common stock via a restricted stock unit (RSU) grant recorded at $0 cost. After the award, his direct beneficial ownership rose to 62,850 shares, a total that includes unvested RSUs.
The explanatory note states that one-sixteenth of the RSU award vests every three calendar months, provided employment is maintained. No sales or derivative transactions were disclosed, and Table II shows no option activity. The filing therefore reflects routine equity compensation, not an open-market transaction, and does not by itself signal a directional view on AEHR’s valuation.
Aehr Test Systems (AEHR) director Rhea J. Posedel has filed a Form 4 reporting the grant of 10,575 restricted stock units (RSUs) on 07/02/2025. The RSUs carry no cash exercise price and will vest in equal eighths at the end of each three-month period, contingent on continued board service. Following the award, the director’s direct ownership rises to 71,163 shares, while an additional 470,977 shares are held indirectly through a trust, bringing total beneficial ownership above 542,000 shares.
The filing also references earlier ESOP plan distributions that are already reflected in the current share count and do not constitute new market transactions. No derivative securities were exercised or disposed of, and there were no open-market purchases or sales disclosed. While RSU grants are routine board compensation, the increased equity stake further aligns the director’s interests with shareholders.
- Transaction type: RSU award (code “A”)
- Shares acquired: 10,575
- Total direct shares after grant: 71,163
- Total indirect shares: 470,977 (via trust)
- Vesting: 1/8 every three months
No price was paid for the RSUs, and the filing is unlikely to be materially market-moving on its own, though it signals continued long-term commitment from a key board member.